forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide Receptor Agonist Market Size and Strategies To 2035 GLP-1 Nutritional Support Market Size

Other reasons included other health events unrelated to the treatment course (nine), hesitancy about the treatment (five), pharmacotherapy being part of bariatric preoperative preparation (four), treatment being paused/stopped after achieving desired body weight (four), communication issues related to required documentation (four), medication hold due to surgical procedure (two), other personal reasons (two) and patients no longer meeting the BMI criteria for obesity pharmacotherapy (one)

This study underscores the importance of exploring new therapeutic avenues for PCa, particularly for patients with metabolic syndrome and diabetes

Is Bariatric Surgery the Easy Way Out

By: Kristin Brooks Managing Editor, Contract Pharma Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases

doi: 10.1016/j.jns.2004.05.007

However, there can be exceptions to this general rule